SQ-LIP-000025 · v1.6 (current) · machine-readable JSON →

What specific genetic variants or inheritance patterns have been identified in lipedema?

Knowledge freshness = share of the 23 indexed evidence sources from the last 5 years (newest 2026, oldest 2010) . Low freshness flags an ageing evidence base — not that the answer is wrong.

Evidence over time

consistent   conflicting   refining / contextual Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline.

Answer over time

Each node is a published version of the answer — open one to read the answer exactly as it stood then.

Consistent claims

• SCR-LIP-000287 consistent
  In a case-control study, carriers of the IL-6 rs1800795 G allele had a 5.92-fold higher risk of lipedema (OR=5.92, 95%CI 1.983–17.711, p<0.001), and DXA-derived body composition indices (reduced WHR 0.73 vs 0.79, higher lower-limb FM% 48.90% vs 42.55%) combined with genetic analysis were proposed as tools for differential diagnosis between lipedema, normal-weight obesity, and obesity.
  The role of IL-6 gene polymorphisms in the risk of lipedema — Di Renzo L et al. (2020)
• SCR-LIP-000216 consistent
  A 305-gene NGS panel applied to 162 lipedema patients identified 21 heterozygous deleterious variants in 17 patients (10.5%) across 12 genes (PLIN1, LIPE, PPARG, POMC, NR0B2, GCKR, NPC1, ALDH18A1, GHR, INSR, RYR1, PPARA), most involved in steroidogenesis, lipid homeostasis, and insulin signaling, including PLIN1 c.722T>C linked to familial partial lipodystrophy type 4.
  A Multi-Gene Panel to Identify Lipedema-Predisposing Genetic Variants by a Next-Generation Sequencing Strategy — Michelini et al. (2022) · Lipedema: Progress, Challenges, and the Road Ahead — Cifarelli (2025)
• SCR-LIP-000217 consistent
  This systematic review reports specific genetic findings in lipedema including an AKR1C1 missense variant (Michelini 2020) associated with reduced progesterone clearance and increased adipogenesis, a familial Pit1 mutation causing GH and testosterone deficiency (Bano 2010), and upregulation of ZNF423 and CAV1 dysfunction, supporting a possible genetic susceptibility component.
  Impact of hormones on lipedema development: a systematic literature review — Lüchinger et al. (2026) · Lipedema Research—Quo Vadis? — Ernst et al. (2023)
• SCR-LIP-000219 consistent
  In a series of 67 probands, 14.9% had at least one affected first-degree relative (all affected relatives female), X-chromosome linkage analysis in the largest family excluded X-linked dominant inheritance (lod scores < -2) favoring autosomal dominant inheritance with sex limitation, and onset at puberty in 55% of probands plus near-exclusive female occurrence suggested estrogen-dependent expression.
  Lipedema: An inherited condition — Child et al. (2010)
• SCR-LIP-000234 consistent
  This narrative review describes lipedema as having a hereditary component with autosomal dominant familial inheritance, and notes shared and distinct genetic markers between lipedema and lymphedema.
  Current Mechanistic Understandings of Lymphedema and Lipedema: Tales of Fluid, Fat, and Fibrosis — Duhon et al. (2022)
• SCR-LIP-000235 consistent
  This review reports lipedema as polygenic with familial history in 30-89% of cases, citing a 2022 GWAS (130 carriers) identifying 6 regions (CPE, ZNF25, ZNF33A linked to estrogen biology), a UK Biobank study (24,450 women) finding 18 loci replicating VEGFA and GRB14-COBLL1, a partial loss-of-function missense variant in AKR1C1 in a non-syndromic lipedema family, and a multigene panel of 305 loci finding 17 probable deleterious lesions in 21/162 participants, with no single causal gene and no overlap with primary lymphedema or lipodystrophies.
  Unraveling lipedema: comprehensive insights and the path to future discoveries — Faria et al. (2025) · Genome-wide association study of a lipedema phenotype among women in the UK Biobank identifies multiple genetic risk factors — Klimentidis et al. (2023) · Investigation of clinical characteristics and genome associations in the ‘UK Lipoedema’ cohort — Grigoriadis et al. (2021)
• SCR-LIP-000236 consistent
  A GWAS of a UK lipedema cohort (n=130) identified a suggestive association (not genome-wide significant) at SNP rs1409440 (OR_meta 2.01; P_meta 4×10⁻⁶) located upstream of LHFPL6, a gene involved in lipoma formation, with additional support from an independent 100,000 Genomes replication cohort.
  Investigation of clinical characteristics and genome associations in the ‘UK Lipoedema’ cohort — Grigoriadis et al. (2022)
• SCR-LIP-000238 consistent
  This systematic review reports that lipedema most likely follows autosomal dominant inheritance with incomplete penetrance and sex limitation (positive family history in up to 64% of women), identifies no confirmed gene for primary non-syndromic lipedema, and catalogs syndromic associations (POU1F1A c.196C>T p.Pro24Leu; NSD1 p.Cys2175Ser/Sotos; 7q11.23 deletion/Williams-Beuren with ELN, FZD9, MLXIPL; ABCC6/PXE; ALDH18A1/cutis laxa III) plus 17 GWAS/animal-model candidate genes (e.g., LYPLAL1, TBX15, HOXC13, RSPO3, VEGFA, PROX1, VEGFR3, PRDM16).
  Genetics of lipedema: new perspectives on genetic research and molecular diagnoses — Paolacci S et al. (2019)
• SCR-LIP-000239 consistent
  This narrative review reports that lipedema follows a female-preferential autosomal dominant inheritance pattern and is associated with altered expression of specific genes including CCND1, ZNF423, CYP19A1 (aromatase), COL6A3, and MMP14, while noting that genetic studies remain underpowered.
  Lipedema: Insights into Morphology, Pathophysiology, and Challenges — Poojari et al. (2022)
• SCR-LIP-000240 consistent
  This review identifies specific lipedema-associated variants in AKR1C genes, including the familial AKR1C1 p.Leu213Gln (L213Q) mutation segregating across three generations and reducing catalytic efficiency ~50%, the gain-of-function AKR1C2 Ser320PheTer2 mutation, AKR1C2 overexpression in 24% (5/21) of patients without coding mutations, and regulatory SNPs rs28571848 (glucocorticoid receptor site) and rs34477787 (RORα site) that increase AKR1C2/AKR1C3 expression and truncal fat mass independent of BMI.
  From rare familial mutations to multifactorial disease: aldo-keto reductase 1C enzymes as a central biological pathway in lipedema — Vainberg et al. (2026) · Aldo-Keto Reductase 1C1 (AKR1C1) as the First Mutated Gene in a Family with Nonsyndromic Primary Lipedema — Michelini et al. (2020)
• SCR-LIP-000241 consistent
  Targeted NGS and molecular dynamics simulations identified three missense AKR1C1 variants (L54V, L54F, N280K) in lipedema patients that disrupt substrate or cofactor (NADP+) binding, and screening of gnomAD identified 8 rare AKR1C1 polymorphisms as potentially pathogenic, extending AKR1C1 as a candidate gene for autosomal dominant non-syndromic lipedema.
  AKR1C1 and hormone metabolism in lipedema pathogenesis: a computational biology approach — Kaftalli J et al. (2023)

Conflicting claims

• None indexed yet.

Refining / contextual

• SCR-LIP-000215 refines
  Family-based exome sequencing of 31 individuals from 9 lipedema families identified candidate variants in 469 genes with no single gene shared across all families, supporting genetic heterogeneity rather than a Mendelian single-gene cause, with gene ontology enrichment in vasopressin receptor activity (AVPR1A, AVPR2), microfibril binding (FBN, ELN, LTBP), and patched binding (PTCH1/2, Hedgehog pathway).
  A Family-Based Study of Inherited Genetic Risk in Lipedema — Morgan et al. (2024)
• SCR-LIP-000218 context
  A systematic review of lipedema pathology reported that, despite growing histological and molecular research, the aetiology remains largely uncertain; it noted differential gene expression in lipedema adipose-derived stem cells (3429 genes, including cell-cycle genes Bub1, CDC20, BIRC5 per Ishaq) but did not identify specific inherited variants or defined inheritance patterns.
  Auf der Suche nach der Evidenz: Eine systematische Übersichtsarbeit zur Pathologie des Lipödems — Funke et al. (2023)
• SCR-LIP-000225 context
  This review proposes that dysregulated estrogen signaling in adipose tissue—via an increased ERα/ERβ ratio in gluteofemoral adipocytes or excessive local paracrine estrogen production by adipocyte steroidogenic enzymes—drives the excessive subcutaneous fat accumulation in lipedema, and cites whole-exome sequencing linking lipedema to variants in sex hormone genes, with onset coinciding with hormonal fluctuation periods such as puberty, pregnancy, and menopause.
  Lipedema and the Potential Role of Estrogen in Excessive Adipose Tissue Accumulation — Katzer et al. (2021)
• SCR-LIP-000141 context
  In a Saudi cross-sectional study of 115 patients with lower-limb edema, lipedema was clinically confirmed in 71%, affected only women with mean age 38.6 years and mean BMI 30.5, with disease onset typically at ages 20-39, perceived triggers being puberty (49%), pregnancy (22%), and massive weight loss (22%), a positive family history in 46% (predominantly mothers and sisters), and 77% being previously undiagnosed.
  Characteristics and Clinical Features of Patients with Lipedema in Saudi Arabia: A Cross-sectional Comprehensive Assessment — Alosaimi et al. (2024)
• SCR-LIP-000393 context
  A PCR adipogenesis array of 84 genes in lipedema adipose tissue versus matched controls found 5 differentially expressed genes (upregulated CCND1 2.16x; downregulated CEBPD -2.7x, CFD -1.88x, NCOR2 -1.81x, KLF4 -3.57x), reflecting altered gene expression rather than identifying germline genetic variants or inheritance patterns.
  Adipose Tissue Hypertrophy, An Aberrant Biochemical Profile and Distinct Gene Expression in Lipedema — Felmerer et al. (2020)
• SCR-LIP-000314 context
  This narrative review proposes that lipedema involves a common genetic alteration—an imbalance of estradiol receptors (ERα > ERβ) in adipose tissue present in all cases—combined with physiological hormonal fluctuations (puberty, pregnancy, menopause), endocrine disruptors, and estrogen-dependent gynecological disorders, citing associations such as menstrual irregularities (43%) and PCOS (17%) in women with lipedema.
  Hormonal Links between Lipedema and Gynecological Disorders: Therapeutic Roles of Gestrinone and Drospirenone — Viana & Câmara (2025)
• SCR-LIP-000431 refines
  Multi-omics profiling of late-stage lipedema identified over 5,000 differentially methylated CpG sites and hypomethylation of the AKT1 promoter correlating with increased AKT1 expression and phosphorylation, positioning enhanced AKT pathway signaling as a central epigenetic and molecular alteration rather than a defined germline inheritance pattern.
  Santella et al. Journal of Translational Medicine (2026)

Major uncertainty

Whether any of the proposed candidate genes (AKR1C1, PLIN1, IL-6, LHFPL6) or GWAS loci are causal versus incidental remains unresolved, as most rest on single families, small unreplicated cohorts, or computational prediction; the discovery GWAS used an inferred rather than clinically confirmed phenotype, and no adequately powered, clinically diagnosed, replicated study has established the definitive genetic architecture or a validated inheritance model.

Version history

• SQ-LIP-000025 · v1.6 — 2026-08-30 — This update added a multi-omics late-stage lipedema study (AKT1 promoter hypomethylation with increased AKT1 signaling) and a narrative review proposing a common ERα>ERβ estrogen-receptor imbalance, both reinforcing molecular/epigenetic rather than germline-inheritance mechanisms. · view this version
• SQ-LIP-000025 · v1.5 — 2026-06-02 — Answer recompiled after human curation of the claim set. · view this version
• SQ-LIP-000025 · v1.4 — 2026-05-31 — This update reinforced existing candidates rather than adding new ones, providing a second UK GWAS (n=130 with 100,000 Genomes replication) of suggestive loci linked to lipoma formation/hormone biosynthesis/lipid hydroxylation, a confirmatory whole-exome family study detailing the AKR1C1 c.638T>A p.L213Q variant (3 affected/9 unaffected, with quantified kcat/Km loss), a new familial-history prevalence figure (46% in a Saudi cohort of 115), and an adipogenesis-array expression study (CCND1 up; CEBPD/CFD/NCOR2/KLF4 down) that informs context but identifies no germline variants. · view this version
• SQ-LIP-000025 · v1.3 — 2026-05-31 — Answer recompiled after human curation of the claim set. · view this version
• SQ-LIP-000025 · v1.2 — 2026-05-31 — This update strengthened the moderate-grade GWAS basis (UK Biobank 18 loci with VEGFA/GRB14-COBLL1/ADAMTS9/LYPLAL1/RSPO3 and ~5.13% SNP heritability), explicitly added X-linked dominant exclusion via linkage favoring autosomal dominant with sex limitation, expanded the AKR1C-family candidate evidence (familial AKR1C1 L213Q across three generations plus L54V/L54F/N280K and AKR1C2 variants/regulatory SNPs), and catalogued syndromic gene associations and additional candidate/expression genes. · view this version
• SQ-LIP-000025 · v1.1 — 2026-05-31 — This update established the first indexed answer, compiling moderate-grade family-based exome and NGS-panel evidence for genetic heterogeneity (469-gene and 12-gene candidate sets), reported familial occurrence with proposed X-linked/autosomal dominant incomplete-penetrance inheritance, and registered specific lower-grade candidate findings (AKR1C1, Pit1, ZNF423, CAV1, IL-6 rs1800795). · snapshot not archived
• SQ-LIP-000025 · v1.0 — 2026-05-31 — Question created (promoted from SQ-LIP-D000008). · snapshot not archived

Key references

DOI:10.26355/eurrev_202003_20690 · DOI:10.1089/lrb.2023.0065 · DOI:10.3390/jpm12020268 · DOI:10.1111/obr.13953 · DOI:10.1007/s00404-026-08318-1 · DOI:10.3390/jpm13010098 · DOI:10.1055/a-2183-7414 · DOI:10.1002/ajmg.a.33313 · DOI:10.3390/ijms23126621 · DOI:10.1038/s44324-025-00093-y · DOI:10.1038/s41431-022-01231-6 · DOI:10.1101/2021.06.15.21258988 · DOI:10.1371/journal.pone.0274867 · DOI:10.3390/ijms222111720 · DOI:10.26355/eurrev_201907_18292 · DOI:10.3390/biomedicines10123081 · DOI:10.4081/vl.2026.15495 · DOI:10.3390/ijms21176264 · DOI:10.26355/eurrev_202312_34698 · DOI:10.1097/gox.0000000000006173 · DOI:10.1016/j.jss.2020.03.055 · DOI:10.9734/jammr/2025/v37i25731 · DOI:10.1186/s12967-026-07726-w

← All questions